Miyazaki, Koji, Satoshi Komatsu, Mitsuo Ikebe, Richard A. Fenton, and James G. Dobson, Jr. Protein kinase C⑀ and the antiadrenergic action of adenosine in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 287: H1721-H1729, 2004. First published June 17, 2004 10.1152/ajpheart.00224.2004.-Adenosine-induced antiadrenergic effects in the heart are mediated by adenosine A1 receptors (A1R). The role of PKC⑀ in the antiadrenergic action of adenosine was explored with adult rat ventricular myocytes in which PKC⑀ was overexpressed. Myocytes were transfected with a pEGFP-N1 vector in the presence or absence of a PKC⑀ construct and compared with normal myocytes. The extent of myocyte shortening elicited by electrical stimulation of quiescent normal and transfected myocytes was recorded with video imaging. PKC⑀ was found localized primarily in transverse tubules. The A1R agonist chlorocyclopentyladenosine (CCPA) at 1 M rendered an enhanced localization of PKC⑀ in the t-tubular system. The ␤-adrenergic agonist isoproterenol (Iso; 0.4 M) elicited a 29 -36% increase in myocyte shortening in all three groups. Although CCPA significantly reduced the Isoproduced increase in shortening in all three groups, the reduction caused by CCPA was greatest with PKC⑀ overexpression. The CCPA reduction of the Iso-elicited shortening was eliminated in the presence of a PKC⑀ inhibitory peptide. These results suggest that the translocation of PKC⑀ to the t-tubular system plays an important role in A 1R-mediated antiadrenergic actions in the heart. ␤-adrenergic; cardiomyocyte shortening; transfection; t tubules; PKC⑀ translocation ADENOSINE is known to exert numerous effects in the heart. This endogenous nucleoside via adenosine A 1 receptors (A 1 R) causes antiadrenergic (12), antiarrthymogenic (7, 19), and preconditioning (15, 17) actions in the myocardium. The antiadrenergic action of adenosine involves reductions in ␤-adrenergic catecholamine-induced increases in adenylyl cyclase activity (30, 43, 45) , cAMP formation (10, 51), PKA activation (12), myocardial protein phosphorylation (18), intracellular Ca 2ϩ transient magnitude (19), and cardiac atrial (11, 42) and ventricular (12, 46, 51) contractility. Both the A 1 R-mediated antiadrenergic actions (40) and preconditioning (29, 49) appear to involve PKC activity. There are at least 12 isoforms of PKC known to exist in tissues (35), and activation fosters their translocation to anchor proteins in various subcellular locations (37). PKC⑀ along with PKC-␣ and PKC␦ are the dominant isoforms present in adult rat cardiomyocytes (9, 47). Because A 1 R stimulation has been reported to activate PKC␦ in freshly isolated rat ventricular myocytes (22), the possibility that this adenosine receptor activates PKC⑀ was explored.
ADENOSINE is known to exert numerous effects in the heart. This endogenous nucleoside via adenosine A 1 receptors (A 1 R) causes antiadrenergic (12) , antiarrthymogenic (7, 19) , and preconditioning (15, 17) actions in the myocardium. The antiadrenergic action of adenosine involves reductions in ␤-adrenergic catecholamine-induced increases in adenylyl cyclase activity (30, 43, 45) , cAMP formation (10, 51) , PKA activation (12) , myocardial protein phosphorylation (18) , intracellular Ca 2ϩ transient magnitude (19) , and cardiac atrial (11, 42) and ventricular (12, 46, 51) contractility. Both the A 1 R-mediated antiadrenergic actions (40) and preconditioning (29, 49) appear to involve PKC activity. There are at least 12 isoforms of PKC known to exist in tissues (35) , and activation fosters their translocation to anchor proteins in various subcellular locations (37) . PKC⑀ along with PKC-␣ and PKC␦ are the dominant isoforms present in adult rat cardiomyocytes (9, 47) . Because A 1 R stimulation has been reported to activate PKC␦ in freshly isolated rat ventricular myocytes (22) , the possibility that this adenosine receptor activates PKC⑀ was explored.
The present study was undertaken to ascertain whether PKC⑀ plays a role in the antiadrenergic effects caused by A 1 R stimulation. This possibility was investigated by overexpressing PKC⑀ in isolated primary cultured rat ventricular myocytes and determining whether the enzyme could be activated/translocated by A 1 R stimulation in a manner consistent with its involvement in the antiadrenergic action of adenosine. The findings indicate that the A 1 R-elicited activation of PKC⑀ is associated with potentiation of the antiadrenergic actions of adenosine in ventricular myocytes transfected with PKC⑀.
METHODS

Isolation of ventricular myocytes.
Myocytes were isolated from rat hearts using collagenase and hyaluronidase according to procedures previously reported (45) . The harvested rectangular myocytes displayed no spontaneous contractions, excluded Trypan blue, and were capable of contracting upon electrical stimulation. These myocytes were transfected with PKC⑀ as described below. Male SpragueDawley rats (Harlan; Indianapolis, IN, or Charles River; Wilmington, MA) 3-4 mo of age and weighing 250 -325 g were used to obtain ventricular myocytes for these studies. The rats were maintained and used in accordance with recommendations in the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and the guidelines of the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School.
Construction of the vector. Rabbit PKC⑀ cDNA was cloned into the BamH1site of the pEGFP-N1 mammalian expression vector (Clontec). The green fluorescent protein (GFP) moiety was placed at the COOH-terminal end of the PKC⑀ molecule to avoid the potential disruption of the regulatory properties of PKC⑀ and the binding to the cellular elements that is thought to involve the NH 2-terminal portion of the molecule. To avoid the effect of the COOH-terminal GFP moiety on the proper folding of the PKC⑀ molecule, a flexible linker sequence consisting of a 15-amino acid residue (LQSTVPRARDPP-VAT) was inserted between the two moieties.
Transfection. Isolated ventricular myocyte transfection was performed using GeneSHUTTLE-20 (Quantum Biotechnologies; Montreal, Quebec, Canada) according to the instructions of the supplier. Briefly, 1 g of pEGFPN1-PKC⑀ DNA was diluted with 100 l of minimal essential medium (MEM) and transferred to the diluted liposome solution containing 5 l of GeneSHUTTLE-20 in 100 l of MEM. After incubation for 30 min, the DNA/liposome complex solutions were added to the ventricular myocytes in a 35-mm dish. Cells were used in experiments after overnight incubation at 37°C with a 5% CO 2 atmosphere.
Cos7 cells were transfected with the GFP-PKC⑀ expression vector or pEGFPN1 by electroporation as described previously by us (36) . In brief, the cells were treated with ice-cold 5% trichloroacetic acid followed by sonication. The samples were then dissolved in a 5% SDS-0.5 M NaHCO 3 buffer and subjected to SDS-PAGE followed by Western blotting.
Extraction, immunoprecipitation, and assay of PKC. PKC⑀-GFP was extracted from transfected Cos7 cells in buffer containing 0.5 M KCl, 10% glycerol, 0.025% Triton X-100, 1 mM ATP, 1 mM PMSF, 0.2 mg/ml N-␣-p-tosyl-L-lysine chloromethyl ketone, 1 mM N-␣-ptosyl-L-arginine methyl ester, 1 mM DTT, 10 g/ml leupeptin, and 30 mM Tris ⅐ HCl (pH 7.5). Anti-GFP antibodies conjugated with protein A beads were added to perform immunoprecipitation. The immunoprecipitated samples were assayed for PKC activity in a buffer containing 0.4 mg/ml histone III, 25 mM PIPES, 1 mM EGTA, 0.05 M KCl, 1 mM MgCl 2, 0.1 mg/ml phosphatidyl serine, and 0.05 mM [␥-
32 P]ATP (pH 7.0) at 25°C in the presence and absence of 50 ng/ml phorbol 12-myristate 13-acetate (PMA). The kinase activity is reported as micromoles of 32 P incorporated per minute per milligram of protein.
Immunocytochemistry and imaging. Transfected and nontransfected ventricular myocytes were cultured for 4 h on poly-L-ornithinecoated glass coverslips to allow attachment. After attachment, the myocytes were exposed to the A 1R agonist chlorocyclopentyladenosine (CCPA) and/or the A 1R antagonist dipropylcyclopentylxanthine (DPCPX) as described in the appropriate figures. Myocytes were fixed in 4% formaldehyde for 10 min and permeabilized with 0.1% Triton X-100 in suffusion solution (SS). SS contained (in mM) 136.4 NaCl, 4.7 KCl, 1.0 CaCl 2, 10 HEPES, 1.0 NaHCO3, 1.2 MgSO4, 1.2 KH2PO4, 10 glucose, 0.6 ascorbate, and 1.0 pyruvate. After being blocked with 3% BSA in SS at room temperature for 1 h, the preparations were incubated with rabbit antibodies against PKC⑀, PKC␦ (Calbiochem; San Diego, CA), and GFP (Medical & Biological Laboratories; Watertown, MA) at 4°C for 12-16 h. These antibodies were used to assess the presence of endogenous PKC⑀ and PKC␦ and the level of PKC⑀ transfection in the myocytes. After being washed with SS three times, they were incubated with fluorescence-labeled Cy5-or FITC-conjugated anti-rabbit secondary antibodies (Jackson ImmunoResearch; West Grove, PA, or Molecular Probes; Eugene, OR, respectively) at 37°C for 1 h. Excess secondary antibody was removed, and the samples were mounted in 3% 1,4-diazabicyclo(2.2.2)octane (DABCO, Sigma)-90% glycerol in SS. The immunostained samples were viewed using a Leica DM IRBE inverted microscope equipped with a TCS SP2 confocal system, a 65-mW argon laser, two helium/neon lasers (1.2 and 10 mW), and differential interference contrast accessories (Leica Microsystems; Heidelberg, Germany). Images were acquired and analyzed with LCS software and Adobe Photoshop 6.0 software (Adobe Systems; San Jose, CA).
PAGE and immunoblotting. Ventricular myocytes were dissolved and subjected to PAGE and immunoblotting as previously described (14) . Primary rabbit PKC⑀ and PKC␦ antibodies were used and visualized with a secondary anti-rabbit antibody conjugated to horseradish peroxidase.
PKC-⑀ inhibitor peptide. Ventricular myocytes were rendered permeable to PKC⑀ inhibitory peptide (Glu-Ala-Val-Ser-Leu-Lys-ProThr, EMD Biosciences; La Jolla, CA) by exposure to a permeabilization buffer (PB) consisting of 20 mM HEPES (pH 7.4), 10 mM EGTA, 140 mM KCl, 150 g/ml peptide, 6 mM ATP, 2 M ␤-escin, and 0.02% DMSO for 10 min at room temperature. After the permeabilization, the myocytes were returned to SS by exposing the cells to gradually increasing concentrations of Ca 2ϩ stepwise every 2 min from 0, 50, 100, 300, and 500, to 1,000 M in SS containing 6 mM ATP and no initially added Ca 2ϩ . The myocytes were suffused with SS for 20 min and stimulated to contract at 12 beats/min.
Myocyte contractile function for overexpression studies. Transfected or nontransfected ventricular myocytes contained in 35-mm dishes with 3.0 ml of SS were placed on an inverted fluorescent microscope (Diaphot, Nickon) equipped with a SIT camera (VE 1000 SIT, DAGE MTI). A 35-mm plastic ring equipped with platinum wire electrodes was used to initiate myocyte contraction every 10 s. In addition, the ring also possessed an inflow and aspiration outflow for continual suffusion of the myocytes with SS at 0.4 ml/min. The SIT camera and a JVC CR-6004 videocassette recorder (Technical Video Resources; Fairfield, CT) were used to record myocyte shortening with each contraction. After the transfected and nontransfected myocytes were delineated in a fluorescent field, a visual field was used to assess shortening of the myocytes. The extent of myocyte shortening was determined by playback and printing of the relaxed and fully shortened images of each myocyte using a Sony UP-811 video graphic printer. The difference in the myocyte length between the two images provided the extent of shortening. Shortening is expressed in micrometers.
Protocol for assessing myocyte contractile function. The ventricular myocytes were equilibrated for 30 -40 min without electrical stimulation and continually suffused with fresh SS (Fig. 1) . A train of four contractions 10 s apart was then recorded as control shortenings. Suffusion was continued with isoproterenol (Iso), a ␤1-adrenergic receptor agonist, at 0.4 M present in the SS for 10 min, and a train of four contractions was recorded for the first sequence. In the second sequence, suffusion was continued with the Iso together with the A1R agonist CCPA present at a concentration of 2 M in the SS for 10 min. A train of four shortenings was recorded. In the third sequence, Iso, CCPA, and the A1R antagonist DPCPX (2 M) were included together in the SS for 10 min. A final train of four shortenings was recorded.
Myocyte contractile function in the presence of PKC⑀ inhibitor peptide. Myocyte contractile shortening was determined using an IonOptix System (Milton, MA) in a continuous suffusion chamber as previously described (13) . Briefly, myocytes were stimulated to contract at 12 beats/min and exposed to 0.4 M Iso, 2 M CCPA, or a combination of these two agents for 4 min in either the absence or presence of a PKC⑀ inhibitor peptide. Myocyte cell shortening was recorded and expressed in micrometers.
Statistical methods. All data are presented as means Ϯ SE. ANOVA was performed with additional testing using the StudentNewman-Keuls test (Statmost, DatAxiom Software; Los Angeles, CA). A probably (P value) of Ͻ0.05 was accepted as indicating a statistically significant difference.
Materials. Buffer salts acids and general laboratory reagents were obtained from Fisher Scientific (Medford, MA). Iso, ascorbic acid, CCPA, DPCPX, HEPES, DMSO, BSA, poly-L-ornithine, ␤-escin (aescin), and formaldehyde were purchased from RBI/Sigma Chemical (St. Louis, MO). The anti-PKC⑀ and PKC␦ rabbit polyclonal and goat anti-rabbit antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-GFP rabbit polyclonal antibodies were obtained from MBL (Ina, Japan). Triton X-100 was from RPI (Mt. Prospect, IL) and MEM was from GIBCO/BRI (Rockville, MD). Iso (10 mM) was prepared in 0.1% Na 2S2O5 fresh daily and, upon final dilution, is a solution of 1 mM ascorbic acid. CCPA and DPCPX (10 mM) were prepared in DMSO fresh daily. 
RESULTS
Overexpression of GFP-tagged PKC⑀ in cardiomyocytes.
To observe the effects of PKC⑀ on the antiadrenergic action of A 1 R stimulation, GFP-tagged PKC⑀ was overexpressed in isolated ventricular myocytes using the mammalian expression vector pEGFPN1/PKC⑀. The GFP tagging makes it possible to identify the transfected cells during contraction monitoring. To ensure that GFP signals observed in cells represent GFP-PKC⑀ but not the degradation products, the transfected cells were subjected to Western blot analysis using anti-GFP antibodies (Fig. 2) . We recognized the expressed GFP-tagged PKC protein as a single band at the expected molecular weight of the GFP-PKC⑀ chimera, and there were no degradation products having the GFP moiety. The results indicate that the GFP signals in cells solely represent GFP-tagged PKC⑀.
To examine whether COOH-terminal GFP hampers PKC⑀ function, PKC⑀-GFP was extracted from transfected Cos7 cells and immunoprecipitated, and the precipitate was assayed for PKC activity as described in METHODS. The kinase activities of PKC⑀-GFP in the presence and absence of PMA were 3.2 and 0.25 mol⅐min Ϫ1 ⅐mg Ϫ1 , respectively. The activity was significantly regulated by PMA, suggesting that the PKC⑀-GFP chimera maintains the authentic PMA-dependent kinase activity.
Detection of endogenous PKC⑀ as revealed using a PKC⑀ antibody indicates that upon exposure of the nontransfected myocyte to CCPA, the enzyme translocates to t-tubular-like structures in the cell (Fig. 3, a and b) . Preincubation of nontransfected myocytes with the A 1 R antagonist DPCPX prevented the CCPA-induced translocation of the enzyme (Fig.  3c) . This is not unusual because PKC⑀ has been reported to translocate to membrane caveolae upon activation in rat cardiomyocytes (48) . In contrast, distribution of endogenous PKC␦ as revealed using a PKC␦ antibody indicates that CCPA does not cause this isoform to translocate (Fig. 3, g and h) . The present results suggest that A 1 R stimulation using CCPA elicits translocation of PKC⑀ to t-tubular-like structures of the ventricular myocytes. Immunoblotting of endogenous PKC⑀ and PKC␦ revealed that both isoforms were present in the myocytes. Although there appeared to be more PKC␦ compared with PKC⑀, the former isoform did not translocate to t-tubularlike structures with CCPA stimulation of the myocytes. In transfected myocytes, GFP-tagged PKC⑀ also moved to t-tubular-like structures with CCPA (Fig. 4, a and b) , and its translocation was hampered by DPCPX (Fig. 4c) . However, the total fluorescent signal in the transfected myocytes was significantly higher than in the nontransfected cells. These results demonstrate that the CCPA-induced translocation of PKC⑀ determined by anti-PKC⑀ antibody staining is not a result of nonspecific signals and that GFP tagging did not interfere with the CCPA-induced translocation of PKC⑀.
Expressed GFP-tagged PKC⑀ was estimated to be approximately fivefold (5.5 Ϯ 0.2; n ϭ 3 experiments) greater in the transfected myocytes compared with endogenous PKC⑀ in nontransfected myocytes. This comparison was obtained by determining the mean value of the total fluorescent intensities of anti-PKC⑀ antibody signals for nontransfected and transfected myocytes (n ϭ 10 cells). It is reasonable to assume that the overexpression of PKC⑀ should enhance the activation of relevant downstream pathways compared with responses in the absence of overexpression.
To more clearly delinate the structure to which PKC⑀ translocated, we compared the localization of the GFP signal and the brightfield image. The localization of GFP was coincident with the I band of the myocyte (Fig. 5 ). Because t tubules are located at the center of the I-band in myocytes, the results suggest that A 1 R stimulation, using CCPA, elicits translocation of PKC⑀ to t-tubular-like structures of the ventricular myocytes.
Cardiomyocyte contractile activity. Overexpression of PKC⑀ in ventricular myocytes increases the A 1 R-mediated reduction of the ␤ 1 -adrenergic elicited contractile response. The average resting myocyte length was 109.5 Ϯ 3.1 m. The myocytes shortened by ϳ10% upon electrical stimulation. With Iso administration at 0.4 M in the SS, the extent of shortening increased to ϳ30%. Overexpression of PKC⑀ by transfection in myocytes had no significant effect on the basal extent of cell shortening (Fig. 6) . A 10-min exposure to Iso caused a 28.9 Ϯ 3.4% and 36.4 Ϯ 3.7% increase in the extent of myocyte shortening above the basal levels of normal and transfected myocytes, respectively. The Iso-induced increase in the shortening was not significantly different between normal and transfected myocytes. In the presence of 2 M CCPA, an A 1 R agonist, the Iso-produced increase in shortening was reduced to only a 12.9 Ϯ 0.7% increase above the basal level of shortening in normal myocytes. However, in transfected myocytes, the CCPA totally inhibited the Iso-elicited increase in the extent of myocyte shortening. To verify that the CCPA inhibition of the Iso-elicited contractile response was due to activation of the A 1 R, the A 1 R antagonist DPCPX was used in both normal and transfected myocytes. DPCPX restored the Iso-induced increase in myocyte shortening in both normal and transfected myocytes to levels not significantly different from the increase in shortening resulting from the administration of Iso alone. These data suggest that the CCPA-induced reduction of the Iso-induced increase in shortening is due to A 1 R stimulation.
Further experiments were conducted by transfecting myocytes with PKC⑀-free vector (null vector). The presence of the expression vector devoid of PKC⑀ in the transfected myocytes did not influence the antiadrenergic action of CCPA. Iso increased shortening by 30.6 Ϯ 1.9% in normal and 32.8 Ϯ 2.5% in null vector-containing myocytes (Fig. 7) . The increase in shortening caused by Iso in the presence of CCPA was 13.1 Ϯ 2.3% and 14.7 Ϯ 2.8% for normal and null vectorcontaining myocytes, respectively. These reductions in the Iso responses were not significantly different. DPCPX restored the Iso-produced increase in shortening in the presence of CCPA. These results indicate that presence of the null expression vector did not influence either the antiadrenergic or Iso-induced contractile response.
Comparison of the antiadrenergic effects observed in normal, PKC⑀-transfected, and null vector-containing myocytes indicates that myocytes in which PKC⑀ is overexpressed display a greater antiadrenergic response (Fig. 8) . The antiadrenergic effect was approximately twofold greater in the PKC⑀-overexposed myocytes, suggesting that PKC⑀ plays an important role in the antiadrenergic action of A 1 R stimulation.
The reduction of the Iso-elicited contractile response caused by CCPA was prevented by using a PKC⑀ inhibitory peptide. Ventricular myocytes rendered permeable to the peptide, as outlined in METHODS, displayed normal contractile function. Upon permeablization, myocytes that were exposed to the peptide shortened similarly to those that were not exposed to peptide (Fig. 9) . Iso at 0.4 M increased shortening by 94.7 Ϯ 19.6% and 141.2 Ϯ 15.8% in myocytes exposed and not exposed to the inhibitory peptide, respectively. Although the peptide tended to increase the Iso contractile response, it was not significant. The inhibitory peptide was without effect on myocyte shortening in the presence of 2 M CCPA alone.
CCPA in the presence of Iso caused only a 46.2 Ϯ 8.9% increase in shortening when myocytes were not exposed to the peptide. However, in myocytes exposed to the peptide, CCPA plus Iso increased shortening by 117.5 Ϯ 14.3%. Thus the PKC⑀ inhibitory peptide prevented the antiadrenergic action of CCPA in Iso-stimulated myocytes. 
DISCUSSION
The present study indicates that A 1 R stimulation results in a translocation of endogenous and overexpressed PKC⑀ to ttubular-like structures of ventricular myocytes. Furthermore, compared with nontransfected ventricular myocytes and myocytes transfected with PKC⑀-free or null vector, overexpression of PKC⑀ in myocytes potentiates the antiadrenergic action of A 1 R stimulation in isoproterenol-stimulated contracting myocytes. Overexpression of PKC⑀ in ventricular myocytes has no effect on basal and Iso-elicited contractions but exerts an effect upon stimulation with the A 1 R agonist CCPA. Although PKC␦ was present in the ventricular myocytes, CCPA did not cause translocation of this isoform of PKC. In addition, a PKC⑀ inhibitory peptide prevented the antiadrenergic effect caused by CCPA in nontransfected myocytes without having a significant influence on basal or Iso-elicited contractions. The results also appear to indicate that ventricular myocyte PKC⑀ requires A 1 R stimulation to manifest an effect. Overall, these findings suggest that PKC⑀ may play an important role in mediating the adenosinergic effects of A 1 R stimulation in cardiac muscle.
Over the past several years, the importance of PKC in signaling pathways modulating heart function has become apparent. Studies have shown that PKC activation influences cardiac contractility (6, 31, 55) , gene expression (37), the development of hypertrophy (1, 52) , and the manifestation of preconditioning of the ischemic myocardium (2, 54) . The PKC isoform PKC⑀ has been consistently detected in adult ventricular myocytes (23, 24, 41) and is observed endogenously in the present study using an antibody to this isoform of the enzyme. Generally, activation of PKC by extracellular agonists elicits the translocation from the cytosol to the membrane fraction of cells. In this study, PKC⑀ appears to translocate to t-tubularlike structures with A 1 R stimulation. This finding is in agreement with previous reports revealing that PKC⑀ translocates to striated structures thought to be the t tubules of the cardiomyocyte as evidenced by the colocalization of the PKC-⑀-GFP construct with ␣-actinin, a structural protein marker for the Z line of the sarcomere (41) . However, the importance of this translocation is not fully understood.
In the myocardium, t-tubular membranes penetrate the cardiomyocytes near the Z lines (20) . L-type Ca 2ϩ channels, inducible nitric oxide (NO) synthase (NOS2) (5), RACK2, the anchor protein for PKC⑀, and A-kinase anchor protein (AKAP) (26) have been found to be localized in the t tubules. Such a position adjacent to sarcoplasmic reticular ryanodine receptors and myofibrils creates the potential for an intricate modulation of excitation-contraction coupling via the regulation of intracellular Ca 2ϩ release and myofilament function (53) . With specific reference to PKA, the close proximity of AKAP to the L-type Ca 2ϩ channel ensures that the activation of PKA via extracellular ␤-adrenergic receptor agonists results in the phosphorylation and activation of the channel (21) . The ensuing increase in Ca 2ϩ current (I Ca ) that elicits an increase in cardiomyocyte contractility would be terminated by the dephosphorylating activity of protein phosphatase 2A also associated with the Ca 2ϩ channel (8 (18) . Second, adenosine has been found to manifest antiadrenergic actions via carboxymethylation of protein phosphatase 2A (34) . The resulting increase in enzyme activity would potentially result in the dephosphorylation of myocardial proteins manifesting the increase in contractility resulting from ␤ 1 -adrenergic stimulation. Third, adenosine has been found to enhance the release of NO from endothelial cells (32) and cardiomyocytes (25) . NO has been reported to play an important role in attenuating the responsiveness of the heart to adrenergic stimulation (28); however, this concept is controversial (27) .
It has recently been reported that PKC plays a role in the adenosine-induced modulation of cardiomyocyte function (31) . In the present study, adenosine was observed to stimulate the translocation of PKC⑀ to the membrane fraction of isolated cardiomyocytes, perhaps as a result of phospholipase D activation (16, 39) . In addition, PKC inhibitors have been found to antagonize adenosine receptor agonist-induced decreases in cardiomyocyte shortening velocity (31) . In the present study, it has been documented that PKC⑀ is translocated to the t tubules of the rat ventricular myocytes in response to A 1 R stimulation. Furthermore, overexpression of PKC⑀ resulted in an augmentation of the antiadrenergic action of adenosine compared with the nontransfected ventricular myocyte. This functional manifestation of PKC⑀ translocation appears to be complex. As a result of the colocalization of RACK2 and L-type Ca 2ϩ channels in the t-tubular membrane, it is plausible that the translocation of PKC⑀ to the t tubules results in the phosphorylation of L-type Ca 2ϩ channels (26) . It has recently been reported that an attenuation of I Ca in rat ventricular myocytes results from the activation of PKC⑀ (23) . Thus it may be presumed that the translocation of PKC⑀ is a normal component of the antiadrenergic action of A 1 R stimulation that is amplified by enhanced levels of PKC⑀. Additional complexity may result from the considerable cross-talk between various signaling pathways in the cell (26) . For example, I Ca is independently increased by ␣ 1 -and ␤ 1 -adrenergic receptors that involve PKC and PKA signaling pathways, respectively. However, ␣ 1 -agonists attenuate the ability of ␤ 1 -agonists to enhance I Ca (3) . With respect to contractile activity, similar interactions have been found to exist between A 1 R and the adenosine A 2 receptor (38) . Perhaps other mechanisms in addition to PKC⑀ translocation are at work influencing the magnitude of I Ca in the ␤ 1 -adrenergic stimulated heart. In addition to the apparent importance of PKC⑀ in the antiadrenergic and cardioprotective actions of A 1 R stimulation, other isoforms of PKC involving G proteincoupled receptors may also be important in cardiac myocytes. For example, there are findings supporting a role of PKC␦ in the preconditioning and long-term protective actions of adenosine and other agonists of G protein-coupled receptors (33, 56) . It is also of interest that PKC⑀ deletion eliminates the preconditioning reduction of infract size in the mouse heart (50). PKC-␣ may be an important determinant of myocyte contractility (4). In summary, the present studies indicate that A 1 R stimulation results in the translocation of PKC⑀ to t-tubular-like structures of ventricular myocytes. Overexpression of PKC⑀ in ventricular myocytes potentates the antiadrenergic action resulting from A 1 R stimulation in contracting myocytes subjected to ␤ 1 -adrenergic stimulation. Furthermore, an inhibitory peptide of PKC⑀ prevented the antiadrenergic action of A 1 R stimulation. These results suggest that PKC⑀ may play an important role in the adenosinergic effects in cardiac muscle resulting from A 1 R activation.
